Clinical Trials for ALS

213 als trials indexed, 90 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding ALS

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. It causes the motor neurons, which control voluntary muscle movements, to gradually deteriorate and die. As these neurons fail, the brain loses its ability to initiate and control muscle movement. Diagnosing ALS typically involves a combination of clinical examination, electromyography (EMG), nerve conduction studies, and ruling out other conditions. There is no single test for ALS, so doctors rely on symptoms and diagnostic criteria to confirm the disease.

Common symptoms of ALS include muscle weakness, twitching (fasciculations), cramping, and stiffness. These symptoms often begin in one part of the body, such as the hands or feet, and then spread to other areas. Difficulty speaking, swallowing, and breathing can occur as the disease progresses. ALS usually starts between the ages of 40 and 70, with most patients diagnosed around age 55. Men are slightly more likely to develop ALS than women. While the exact cause is unknown, risk factors include genetic mutations, environmental exposures, and possibly military service.

ALS is a serious medical condition with significant social impact. It affects about 5 out of every 100,000 people worldwide. The disease is fatal, with most patients living two to five years after diagnosis. ALS also carries a heavy economic burden, including costs for medical care, assistive devices, and lost income. Because the disease affects muscle control, many people with ALS require ongoing support for daily activities. Understanding ALS is important to improve care and develop better treatments.

The ALS Treatment Landscape

The first-line standard of care for ALS focuses on managing symptoms and maintaining quality of life. This includes physical therapy, occupational therapy, and speech therapy to help preserve muscle function and communication. Nutritional support and respiratory care are also essential parts of treatment. Medications such as riluzole are typically prescribed early to slow the progression of the disease. Riluzole works by reducing damage to motor neurons and is often the first drug patients receive after diagnosis.

Beyond riluzole, several second- and third-line treatment options exist. These include edaravone, an antioxidant drug that may help reduce oxidative stress in nerve cells. Other medications address specific symptoms, like muscle spasticity or excessive saliva. Some patients may also receive non-invasive ventilation to support breathing as respiratory muscles weaken. Researchers continue to study different drug classes, including anti-inflammatory agents and neuroprotective compounds, to expand the available treatments for ALS.

Despite these options, significant gaps remain in ALS treatment. Many patients show limited response to current drugs, and side effects can be challenging. Some subgroups of ALS patients, such as those with certain genetic mutations, may not benefit from standard therapies. Research is ongoing to develop treatments that target underlying disease mechanisms and improve outcomes for all patients. Efforts also focus on reducing the burden of symptoms and enhancing quality of life during disease progression.

Why Clinical Trials Matter for ALS

Clinical trials offer patients with ALS access to new treatments that are not yet widely available. Participation often includes closer medical monitoring and the chance to contribute valuable information to science. According to ClinicalTrials.gov, there are currently 213 ALS clinical trials indexed, with 90 of these actively recruiting participants. These trials test a variety of approaches, from new drugs to devices, aiming to find better ways to slow or stop the disease.

Joining a clinical trial involves risks. The efficacy of experimental treatments is not guaranteed, and some participants may receive a placebo instead of the active drug. Additional clinic visits and tests can add to the burden of care. Side effects from investigational treatments are also possible and may vary in severity. It is important for patients and caregivers to weigh these factors carefully before deciding to enroll in a trial.

The landscape of ALS clinical trials includes sponsors from academic institutions, pharmaceutical companies, and cooperative research groups. These organizations work together to design and conduct studies that meet scientific and regulatory standards. ClinicalTrials.gov serves as a comprehensive registry and results database, helping patients and healthcare providers find relevant trials. This transparency supports informed decision-making and advances research efforts in ALS.

What to Look for in a ALS Clinical Trial

Clinical trials are conducted in phases to test the safety and effectiveness of new treatments. Phase 1 trials focus on safety and dosage, usually involving a small number of participants. Phase 2 trials evaluate the treatment’s effectiveness and side effects in a larger group. Phase 3 trials compare the new treatment to the current standard treatment in even larger groups. Phase 4 trials occur after approval to monitor long-term effects. For ALS, many trials do not specify a phase (110), while Phase 2 trials are the most common (19), followed by Phase 1 (17) and Phase 3 (4).

When considering an ALS clinical trial, inclusion criteria help determine who can participate. These often include specific age ranges, such as adults between 18 and 75 years old. Prior treatments may affect eligibility, as some trials require participants to have tried or avoided certain medications. Biomarkers related to ALS can also be used to select participants. Disease stage and duration are common factors, with some trials focusing on early-stage ALS or limiting how long a person has had the condition.

Exclusion criteria are equally important and exist to protect participants and ensure clear results. People with other health conditions, such as heart or kidney disease, may be excluded to avoid complications. Some trials exclude participants taking certain drugs that could interact with the study treatment. Safety thresholds, like minimum lung function or blood counts, are often set to make sure participants can tolerate the treatment and procedures.

Patients should consider practical aspects before joining a trial. The length of the trial can vary from a few months to several years. Visit schedules may require frequent trips to the study site, which could be challenging depending on location and mobility. Travel expenses and accommodations might not always be covered. It is helpful to ask the research team four key questions: What are the possible risks and benefits? How often will I need to visit the clinic? Will I have to stop any current treatments? What support is available if I experience side effects?

Primary Sources and Further Reading

For those seeking more detailed information about ALS and clinical trials, several trusted sources provide up-to-date and reliable content. These resources offer guidance on understanding the disease, treatment options, and the clinical research process. They can help patients and caregivers make informed decisions about participating in clinical trials.

Latest Research and Emerging Treatments for ALS (2026)

Ongoing ALS research includes several Phase 3 trials investigating new drugs for ALS and related conditions. One important study is testing tofersen, a drug aimed at adults with a genetic mutation linked to ALS but who do not yet show symptoms (NCT04856982). Tofersen works by targeting the faulty gene responsible for producing a harmful protein. Early data suggests that reducing this protein might delay or prevent ALS symptoms. For patients at high risk, this could mean more time before symptoms appear, potentially improving quality of life.

Another area of research focuses on managing symptoms and slowing disease progression. The drug NIO752 is being evaluated for Progressive Supranuclear Palsy, a rare neurological disorder with similarities to ALS (NCT07498426). NIO752 is thought to affect brain pathways involved in movement and balance. If successful, this treatment could provide a new option to help control symptoms for patients facing these challenging conditions.

While some trials focus directly on ALS, others explore treatments for related nerve and muscle issues. For example, early intramuscular botulinum toxin injections are being tested to prevent shoulder deformity in babies with obstetrical brachial plexus palsy (NCT03198702). Though not an ALS treatment, this research may inform approaches to muscle and nerve care in ALS patients. These studies reflect a broader effort in ALS new treatment 2026 to improve patient outcomes through targeted therapies and symptom management.

Frequently asked questions about ALS trials

How do I find ALS clinical trials?

The authoritative source for ALS clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 213 als studies are currently indexed. You can search by entering "als" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new als trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most ALS trials in?

Across the 213 als trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many ALS clinical trials are currently recruiting?

As of the latest scan, 90 als trials have a "Recruiting" status on ClinicalTrials.gov, out of 213 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting als trial matches their tracked condition.

Stay informed about als research

Get a weekly briefing with the trials that matter most.

Start monitoring als trials